• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lixte Biotechnology Holdings, Inc. - Common Stock (NQ:LIXT)

    2.870 -0.030 (-1.03%)
    Streaming Delayed Price Updated: 10:20 AM EDT, Apr 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Lixte Biotechnology Holdings, Inc. - Common Stock

    < Previous 1 2 Next >
    Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
    Via Investor Brand Network
    MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year
    Via Investor Brand Network
    Topics Intellectual Property
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
    Via Investor Brand Network
    Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
    Via Investor Brand Network
    When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It
    Via Investor Brand Network
    Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
    Via Investor Brand Network
    Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships
    Via Investor Brand Network
    Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy
    Via Investor Brand Network
    TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline
    Via Investor Brand Network
    Topics Intellectual Property
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research
    Via Investor Brand Network
    Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care
    Via Investor Brand Network
    BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary
    Via Investor Brand Network
    Topics Intellectual Property
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement
    Via Investor Brand Network
    BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
    Via Investor Brand Network
    Topics Intellectual Property
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
    Via Investor Brand Network
    InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
    Via Investor Brand Network
    Topics Intellectual Property
    MissionIRNewsBreaks –  LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
    Via Investor Brand Network
    Topics Intellectual Property
    Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective
    Via Investor Brand Network
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy
    Via Investor Brand Network
    BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit at Morehouse College
    Via Investor Brand Network
    Topics Intellectual Property
    InvestorNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference
    Via Investor Brand Network
    Topics Intellectual Property
    TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy
    Via Investor Brand Network
    Topics Intellectual Property
    BioMedNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
    Via Investor Brand Network
    Topics Intellectual Property
    LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’
    Via Investor Brand Network
    Topics Intellectual Property
    BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Announces $4.3 Million Registered Direct Offering Priced at Market
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
    From Spartan Capital Securities, LLC
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.